My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Virtus Biotech Clinical Trials ETF (NY:BBC)

40.26 -0.90 (-2.19%)

Delayed Quote Updated: 10:06 AM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Virtus Biotech Clinical Trials ETF

Venture Into High-Volatility Corners of the Market With These 3 ETFs ↗

August 29, 2026

BBC, IWC and GDXJ offer diversified exposure to clinical-stage biotech, micro-cap stocks and junior gold miners, high-risk sectors that have posted strong year-to-date gains in 2026.

Via MarketBeat

Topics ETFs

Innovative ETF Strategies That Are Paying Off This Summer ↗

July 27, 2026

Amid record ETF inflows, niche funds like BBC, LATR, and FMED offer targeted exposure to biotech trials, buy-now-pay-later firms, and disruptive medicine, with notable recent returns.

Via MarketBeat

Topics ETFs

Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗

February 27, 2026

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

Via Stocktwits

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗

January 16, 2026

Via Stocktwits

Topics Intellectual Property

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗

January 09, 2026

Via Stocktwits

Why Did UPB Stock Pop 20% In Pre-Market Today? ↗

February 11, 2026

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

Via Stocktwits

Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗

January 07, 2026

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Via Stocktwits

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

ETFs Last Week: Funds Lead The Charge As Markets Stage A Return To Risk-On ↗

April 28, 2025

Investors ditched worries, boosting ETFs like VanEck SMH (+13%) on chip stock rally, Virtus BBC (+7%) on biotech hope, Simplify TESL (+31%) on Musk's focus, Invesco SPHB (+11.5%) on risk appetite,...

Via Benzinga

Topics ETFs Economy Stocks

CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode ↗

April 10, 2025

The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according...

Via Stocktwits

Topics Government

Why Is uniQure Stock Skyrocketing On Tuesday? ↗

December 10, 2024

uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

Via Benzinga

Inflation Cools In June, Triggers Spike In Laggard ETFs ↗

July 12, 2024

ETFs from some beaten-down corners of the market saw smooth trading following the inflation data.

Via Talk Markets

Topics ETFs Economy

5 ETFs Riding High On The Biotech Comeback ↗

July 09, 2022

The high-growth biotech segment has borne the maximum brunt of the broader market sell-off.

Via Talk Markets

Biotech ETF Tops in June: 5 Stocks That Outperform ↗

June 30, 2022

Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%.

Via Talk Markets

4 Sector ETFs That Survived Market Turmoil in June ↗

June 29, 2022

Despite the broad indices’ losses, a few sector ETFs survived the turmoil.

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.